NCT02028117View on ClinicalTrials.gov

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions
Recurrent Platinum Resistant Ovarian Cancer
Interventions
BIOLOGICAL

Enadenotucirev

Oncolytic Virus

Trial Locations (8)

17007

Hospital Universitari de Girona Dr. Josep Trueta, Girona

50009

Hospital Miguel Servet, Zaragoza

Unknown

Clara Campal Comprehensive Cancer Center Hospital, Madrid

MD Anderson Cancer Center, Madrid

START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid

GU2 7WG

The Royal Surrey County Hospital, Guildford

G61 1BD

Beatson Institute, Glasgow

M20 4BX

The Christie Hospital, Manchester

Sponsors

Lead Sponsor

Akamis Bio
All Listed Sponsors
lead

Akamis Bio

INDUSTRY

NCT02028117 - Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients | Biotech Hunter | Biotech Hunter